ErbB2/Her2 antibody (C-Term)

Catalog No. ABIN499802

The Chicken Polyclonal anti-ErbB2/Her2 antibody has been validated for WB, IHC (p) and EIA. It is suitable to detect ErbB2/Her2 in samples from Human, Mouse and Rat.

Quick Overview for ErbB2/Her2 antibody (C-Term) (ABIN499802)

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivity: Human, Mouse, Rat

Host: Chicken

Clonality: Polyclonal

Conjugate: This ErbB2/Her2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Product Details anti-ErbB2/Her2 Antibody

Binding Specificity: C-Term

Specificity: This antibody reacts to erbB-2.

Purification: Affinity chromatography purified via peptide column

Immunogen: erbB-2 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human erbB-2.

Isotype: IgG

Application Details

Application Notes: ELISA. Western Blot: 1 - 2 μg/mL. Immunohistochemistry.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Buffer: PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store the antibody undiluted at 2-8 °C.

Target Details for ErbB2/Her2

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Alternative Name: CD340 / ERBB2 / HER2

Background: The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2

Gene ID: 2064

NCBI Accession: NP_004439

UniProt: P04626

Pathways: RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development